Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) fell 1.9% on Wednesday . The company traded as low as $6.33 and last traded at $6.45. 897,636 shares were traded during trading, a decline of 28% from the average session volume of 1,253,440 shares. The stock had previously closed at $6.33.

A number of research firms have recently weighed in on AUPH. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Tuesday, August 15th. Vetr downgraded Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 price target for the company. in a research note on Wednesday, September 6th. Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 11th. Finally, BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $9.79.

The firm has a 50 day moving average price of $6.29 and a 200-day moving average price of $6.62. The stock’s market capitalization is $344.61 million.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.06 million. On average, analysts anticipate that Aurinia Pharmaceuticals Inc will post ($0.94) earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. bought a new stake in Aurinia Pharmaceuticals during the first quarter worth about $2,202,000. Quantbot Technologies LP bought a new stake in Aurinia Pharmaceuticals during the first quarter worth about $275,000. Two Sigma Securities LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter worth about $240,000. Renaissance Technologies LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter worth about $776,000. Finally, Morgan Stanley raised its holdings in Aurinia Pharmaceuticals by 11,061.7% during the first quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after acquiring an additional 442,138 shares in the last quarter. Institutional investors and hedge funds own 27.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/04/aurinia-pharmaceuticals-inc-auph-trading-down-1-9.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.